Imamura Teruhiko, Kinugawa Koichiro, Nitta Daisuke, Komuro Issei
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo.
Circ J. 2015;79(11):2414-21. doi: 10.1253/circj.CJ-15-0769. Epub 2015 Sep 17.
We previously reported that cardiac resynchronization therapy with defibrillator (CRT-D) is not an appropriate rescue strategy in patients with advanced heart failure (HF), especially those dependent on inotrope infusion, and instead early ventricular assist device (VAD) implantation should be considered. Predictors of response to CRT in such populations, however, remain uncertain.
We studied 67 inpatients aged <65 years old with advanced HF, who received CRT-D between 2007 and 2014. Eleven patients (16%) were responders, in whom LVEF improved >10% at 6-month follow up. On logistic regression analysis, LA volume index (LAVI) <43 ml/m(2)(odds ratio (OR), 36.67; P=0.001) and complete left bundle branch block (CLBBB; OR, 6.663; P=0.032) were significant predictors of response to CRT-D among the baseline variables. Patients with both predictors were associated with improvements in LVEF and plasma B-type natriuretic peptide compared with those with none of these predictors during the 6-month follow up period (P<0.05 for both). VAD-free survival rate was significantly higher in the responders compared with the non-responders during the 2-year study period (86% vs. 52%, P=0.044).
CLBBB and smaller LAVI are novel predictors of response in patients with advanced HF receiving CRT-D in real-world practice. Such responders may be better candidates for CRT-D and delay of cardiac replacement therapy.
我们之前报道过,对于晚期心力衰竭(HF)患者,尤其是那些依赖血管活性药物输注的患者,植入式心脏复律除颤器的心脏再同步治疗(CRT-D)并非合适的挽救策略,相反,应考虑早期植入心室辅助装置(VAD)。然而,这类人群中对CRT反应的预测因素仍不明确。
我们研究了67例年龄小于65岁的晚期HF住院患者,这些患者在2007年至2014年间接受了CRT-D治疗。11例患者(16%)为反应者,其左心室射血分数(LVEF)在6个月随访时提高了>10%。经逻辑回归分析,在基线变量中,左心房容积指数(LAVI)<43 ml/m²(比值比[OR],36.67;P = 0.001)和完全性左束支传导阻滞(CLBBB;OR,6.663;P = 0.032)是对CRT-D反应的显著预测因素。在6个月的随访期内,与无这些预测因素的患者相比,同时具有这两个预测因素的患者LVEF和血浆B型利钠肽水平均有所改善(两者P均<0.05)。在2年的研究期内,反应者的无VAD生存率显著高于无反应者(86%对52%,P = 0.044)。
在实际临床实践中,CLBBB和较小的LAVI是晚期HF患者接受CRT-D治疗时反应的新预测因素。这类反应者可能更适合CRT-D治疗,并可延缓心脏替代治疗。